News

Amphastar boosts pipeline with exclusive licensing deal from Nanjing Anji

Amphastar Pharmaceuticals (AMPH) has entered into an exclusive license agreement with Nanjing Anji Biotechnology for the development, manufacturing, use, and commercialization of three proprietary ...
Pharmabiz7h

Amphastar Pharma’s iron sucrose injection receives US FDA approval to treat iron deficiency anaemia in patients with CKD

Amphastar Pharma’s iron sucrose injection receives US FDA approval to treat iron deficiency anaemia in patients with CKD: Rancho Cucamonga, California Tuesday, August 12, 2025, ...
CNBCTV1810h

Dr. Reddy's, Aurobindo face a near-'lost' opportunity for an important pipeline drug; Here's why

Among Indian generics makers, Iron Sucrose had been considered a key pipeline product for Dr. Reddy’s Laboratories and ...

Viatris, Amphastar Pharmaceuticals Get FDA Approvals of Iron Sucrose Products

Venofer was approved in the U.S. in 2000. It was developed by Vifor Pharma, which is now part of CSL Ltd. American Regent, a unit of Daiichi Sankyo, manufactures and sells it in the U.S. under a ...

Why Is Amphastar Pharmaceuticals (AMPH) Stock Soaring Today

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 10.4% in the morning session after the company announced it received U.S. Food and Drug Administration (FDA) approval for ...
InvestorsHub on MSN22h

Viatris Shares Climb Following FDA Clearance of First Generic Iron Sucrose Injection

Viatris Inc (NASDAQ:VTRS) saw its stock increase by 2.6% after the U.S. Food and Drug Administration approved its Iron ...
InvestorsHub on MSN22h

Amphastar Shares Rise Following FDA Approval of Generic Iron Sucrose Injection

Amphastar Pharmaceuticals (NASDAQ:AMPH) saw its stock increase by 4% after the company announced that the FDA had approved ...

Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer

Viatris (VTRS) stock gains as the FDA OK its generic Iron Sucrose Injection targeting Venofer marketed by Daiichi Sankyo (DSKYF) (DSNKY) and Vifor. Read more here.
Investing.com India1d

Amphastar stock rises after FDA approves generic iron sucrose injection

Investing.com -- Amphastar Pharmaceuticals (NASDAQ: AMPH) stock gained 4% after the company announced FDA approval for its generic version of iron sucrose injection, a treatment for iron deficiency ...

Amphastar Announces FDA Approval for Iron Sucrose Injection, USP

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to ...

Amphastar Pharmaceuticals, Inc.: Amphastar Announces FDA Approval for Iron Sucrose Injection, USP

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer® for the treatment of iron deficiency anemia in patients with chro ...
Benzinga.com5d

Amphastar Pharmaceuticals Reports Financial Results for the Three ...

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025 Rancho Cucamonga, 08/07/2025 / 13:06, PST/PDT - EQS Newswire - Amphastar Pharmaceuticals, Inc ...